Detailed Mechanism Funding and Narrative

Years of mechanism: 2016 2017 2018

Details for Mechanism ID: 18234
Country/Region: Malawi
Year: 2018
Main Partner: Right to Care
Main Partner Program: NA
Organizational Type: NGO
Funding Agency: USAID
Total Funding: $4,163,723 Additional Pipeline Funding: N/A

NOTE: PEPFAR no longer creates activity narratives for each mechanism. In their place, PEPFAR has begun releasing mechanism specific targets that reveal the achievements and programs that are expected of the funding. If available for this mechanism, these targets are presented below.

Mechanism Allocation by Budget Code for Selected Year
Care: Adult Care and Support (HBHC) $337,463
Care: Orphans and Vulnerable Children (HKID) $0
Care: TB/HIV (HVTB) $108,513
Care: Pediatric Care and Support (PDCS) $241,052
Laboratory Infrastructure (HLAB) $0
Strategic Information (HVSI) $0
Health Systems Strengthening (OHSS) $0
Biomedical Prevention: Voluntary Medical Male Circumcision (CIRC) $0
Biomedical Prevention: Blood Safety (HMBL) $0
Biomedical Prevention: Injection Safety (HMIN) $0
Sexual Prevention: Abstinence/Be Faithful (HVAB) $0
Prevention: HIV Testing and Counseling (HVCT) $1,002,338
Sexual Prevention: Other Sexual Prevention (HVOP) $0
Prevention: Injecting and Non-Injecting Drug Use (IDUP) $0
Biomedical Prevention: Prevention of Mother to Child Transmission (MTCT) $0
Treatment: ARV Drugs (HTXD) $0
Treatment: Adult Treatment (HTXS) $1,887,851
Treatment: Pediatric Treatment (PDTX) $586,506
Mechanism Target Information

Since COP2014, PEPFAR no longer produces narratives for every mechanism it funds. However, PEPFAR has now included performance targets or indicator information for each mechanism based on the Monitoring, Evaluation, and Reporting (MER) system. The MER guidance is available on PEPFAR's website https://www.pepfar.gov/reports/guidance/. Note that COP years 2014-2015 were under a previous version of the MER system and the indicators and definitions may have changed as of the new 2.0 guidance.

MER Indicator MER description Target Fiscal Year Target
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Negative 2019 540
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Female, Positive 2019 94
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Negative 2019 810
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 25-29, Male, Positive 2019 74
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Negative 2019 487
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Female, Positive 2019 114
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Negative 2019 694
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 30-34, Male, Positive 2019 174
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Negative 2019 356
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Female, Positive 2019 105
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Negative 2019 592
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 35-39, Male, Positive 2019 184
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Negative 2019 199
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Female, Positive 2019 139
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Negative 2019 765
HTC_TST_DSD HTS_TST_N_DSD_Index_Age_Sex_Result 40-49, Male, Positive 2019 350
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Negative 2019 1,020
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Female, Positive 2019 60
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Negative 2019 846
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 25-29, Male, Positive 2019 30
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Negative 2019 919
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Female, Positive 2019 73
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Negative 2019 726
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 30-34, Male, Positive 2019 73
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Negative 2019 667
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Female, Positive 2019 70
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Negative 2019 621
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 35-39, Male, Positive 2019 75
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Negative 2019 375
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Female, Positive 2019 88
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Negative 2019 800
HTC_TST_DSD HTS_TST_N_DSD_Inpat_Age_Sex_Result 40-49, Male, Positive 2019 145
HTC_TST_DSD HTS_TST_N_DSD_MN_Age_Sex_Result <5, Unknown Sex, Negative 2019 52
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Negative 2019 955
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Female, Positive 2019 51
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Negative 2019 1,488
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 25-29, Male, Positive 2019 54
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Negative 2019 675
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Female, Positive 2019 48
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Negative 2019 1,390
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 30-34, Male, Positive 2019 94
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Negative 2019 679
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Female, Positive 2019 51
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Negative 2019 1,166
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 35-39, Male, Positive 2019 92
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Negative 2019 1,508
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Female, Positive 2019 104
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Negative 2019 1,688
HTC_TST_DSD HTS_TST_N_DSD_OtPITC_Age_Sex_Result 40-49, Male, Positive 2019 171
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Negative 2019 11,110
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 25-29, Female, Positive 2019 289
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Negative 2019 3,844
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 30-34, Female, Positive 2019 90
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Negative 2019 2,563
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 35-39, Female, Positive 2019 63
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Negative 2019 12,686
HTC_TST_DSD HTS_TST_N_DSD_PMTCT_Age_Sex_Result 40-49, Female, Positive 2019 398
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Negative 2019 113
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Female, Positive 2019 16
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Negative 2019 309
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 15-19, Male, Positive 2019 11
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Negative 2019 113
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Female, Positive 2019 16
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Negative 2019 309
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 20-24, Male, Positive 2019 11
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Negative 2019 98
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Female, Positive 2019 12
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Negative 2019 89
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 25-29, Male, Positive 2019 7
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Negative 2019 90
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Female, Positive 2019 14
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Negative 2019 76
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 30-34, Male, Positive 2019 17
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Negative 2019 64
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Female, Positive 2019 14
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Negative 2019 64
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 35-39, Male, Positive 2019 19
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Negative 2019 36
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Female, Positive 2019 16
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Negative 2019 83
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 40-49, Male, Positive 2019 36
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Female, Negative 2019 3
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Negative 2019 16
HTC_TST_DSD HTS_TST_N_DSD_STI_Age_Sex_Result 50+, Male, Positive 2019 4
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Negative 2019 45
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Female, Positive 2019 3
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Negative 2019 42
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 25-29, Male, Positive 2019 3
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Negative 2019 40
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Female, Positive 2019 3
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Negative 2019 36
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 30-34, Male, Positive 2019 8
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Negative 2019 29
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Female, Positive 2019 3
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Negative 2019 31
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 35-39, Male, Positive 2019 8
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Negative 2019 34
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Female, Positive 2019 4
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Negative 2019 40
HTC_TST_DSD HTS_TST_N_DSD_TBC_Age_Sex_Result 40-49, Male, Positive 2019 15
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Negative 2019 4,216
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Female, Positive 2019 249
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Negative 2019 2,842
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 25-29, Male, Positive 2019 105
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Negative 2019 3,797
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Female, Positive 2019 301
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Negative 2019 2,432
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 30-34, Male, Positive 2019 253
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Negative 2019 2,760
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Female, Positive 2019 286
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Negative 2019 2,080
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 35-39, Male, Positive 2019 266
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Negative 2019 1,549
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Female, Positive 2019 369
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Negative 2019 2,682
HTC_TST_DSD HTS_TST_N_DSD_VCT_Age_Sex_Result 40-49, Male, Positive 2019 509
HTC_TST_DSD Number of individuals who received T&C services for HIV and received their test results during the past 12 months 2019 177,679
HTC_TST_DSD Service Delivery Point (Facility) ANC: 10-14, Negative 2019 3,083
HTC_TST_DSD Service Delivery Point (Facility) ANC: 10-14, Positive 2019 91
HTC_TST_DSD Service Delivery Point (Facility) ANC: 15-19, Negative 2019 4,485
HTC_TST_DSD Service Delivery Point (Facility) ANC: 15-19, Positive 2019 128
HTC_TST_DSD Service Delivery Point (Facility) ANC: 20-24, Negative 2019 7,996
HTC_TST_DSD Service Delivery Point (Facility) ANC: 20-24, Positive 2019 215
HTC_TST_DSD Service Delivery Point (Facility) Index: 1-9, Negative 2019 142
HTC_TST_DSD Service Delivery Point (Facility) Index: 1-9, Positive 2019 10
HTC_TST_DSD Service Delivery Point (Facility) Index: 10-14, Female, Negative 2019 31
HTC_TST_DSD Service Delivery Point (Facility) Index: 10-14, Female, Positive 2019 3
HTC_TST_DSD Service Delivery Point (Facility) Index: 10-14, Male, Negative 2019 30
HTC_TST_DSD Service Delivery Point (Facility) Index: 10-14, Male, Positive 2019 3
HTC_TST_DSD Service Delivery Point (Facility) Index: 15-19, Female, Negative 2019 1,303
HTC_TST_DSD Service Delivery Point (Facility) Index: 15-19, Female, Positive 2019 216
HTC_TST_DSD Service Delivery Point (Facility) Index: 15-19, Male, Negative 2019 1,551
HTC_TST_DSD Service Delivery Point (Facility) Index: 15-19, Male, Positive 2019 218
HTC_TST_DSD Service Delivery Point (Facility) Index: 20-24, Female, Negative 2019 1,303
HTC_TST_DSD Service Delivery Point (Facility) Index: 20-24, Female, Positive 2019 216
HTC_TST_DSD Service Delivery Point (Facility) Index: 20-24, Male, Negative 2019 1,551
HTC_TST_DSD Service Delivery Point (Facility) Index: 20-24, Male, Positive 2019 218
HTC_TST_DSD Service Delivery Point (Facility) Index: 50+, Female, Negative 2019 18
HTC_TST_DSD Service Delivery Point (Facility) Index: 50+, Female, Positive 2019 4
HTC_TST_DSD Service Delivery Point (Facility) Index: 50+, Male, Negative 2019 150
HTC_TST_DSD Service Delivery Point (Facility) Index: 50+, Male, Positive 2019 40
HTC_TST_DSD Service Delivery Point (Facility) Index: <1, Negative 2019 18
HTC_TST_DSD Service Delivery Point (Facility) Index: <1, Positive 2019 1
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 1-9, Negative 2019 224
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 1-9, Positive 2019 4
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 10-14, Female, Negative 2019 49
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 10-14, Female, Positive 2019 1
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 10-14, Male, Negative 2019 48
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 10-14, Male, Positive 2019 1
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 15-19, Female, Negative 2019 1,762
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 15-19, Female, Positive 2019 121
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 15-19, Male, Negative 2019 2,791
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 15-19, Male, Positive 2019 95
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Female, Negative 2019 1,762
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Female, Positive 2019 121
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Male, Negative 2019 2,791
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 20-24, Male, Positive 2019 95
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Female, Negative 2019 35
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Female, Positive 2019 2
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Male, Negative 2019 158
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: 50+, Male, Positive 2019 16
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: <1, Negative 2019 28
HTC_TST_DSD Service Delivery Point (Facility) Inpatient: <1, Positive 2019 1
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 1-9, Negative 2019 2,641
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 1-9, Positive 2019 56
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 10-14, Female, Negative 2019 833
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 10-14, Female, Positive 2019 17
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 10-14, Male, Negative 2019 867
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 10-14, Male, Positive 2019 18
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 15-19, Female, Negative 2019 1,229
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 15-19, Female, Positive 2019 82
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 15-19, Male, Negative 2019 3,042
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 15-19, Male, Positive 2019 87
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 20-24, Female, Negative 2019 1,341
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 20-24, Female, Positive 2019 87
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 20-24, Male, Negative 2019 3,212
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 20-24, Male, Positive 2019 95
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 50+, Female, Negative 2019 1,271
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 50+, Female, Positive 2019 57
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 50+, Male, Negative 2019 832
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: 50+, Male, Positive 2019 45
HTC_TST_DSD Service Delivery Point (Facility) Other PITC: <1, Positive 2019 5
HTC_TST_DSD Service Delivery Point (Facility) Pediatric : <5 Negative 2019 1,903
HTC_TST_DSD Service Delivery Point (Facility) Pediatric : <5 Positive 2019 15
HTC_TST_DSD Service Delivery Point (Facility) TB: 1-9, Negative 2019 12
HTC_TST_DSD Service Delivery Point (Facility) TB: 10-14, Female, Negative 2019 1
HTC_TST_DSD Service Delivery Point (Facility) TB: 10-14, Male, Negative 2019 1
HTC_TST_DSD Service Delivery Point (Facility) TB: 15-19, Female, Negative 2019 63
HTC_TST_DSD Service Delivery Point (Facility) TB: 15-19, Female, Positive 2019 5
HTC_TST_DSD Service Delivery Point (Facility) TB: 15-19, Male, Negative 2019 158
HTC_TST_DSD Service Delivery Point (Facility) TB: 15-19, Male, Positive 2019 5
HTC_TST_DSD Service Delivery Point (Facility) TB: 20-24, Female, Negative 2019 63
HTC_TST_DSD Service Delivery Point (Facility) TB: 20-24, Female, Positive 2019 5
HTC_TST_DSD Service Delivery Point (Facility) TB: 20-24, Male, Negative 2019 158
HTC_TST_DSD Service Delivery Point (Facility) TB: 20-24, Male, Positive 2019 5
HTC_TST_DSD Service Delivery Point (Facility) TB: 50+, Male, Negative 2019 7
HTC_TST_DSD Service Delivery Point (Facility) TB: 50+, Male, Positive 2019 1
HTC_TST_DSD Service Delivery Point (Facility) TB: <1, Negative 2019 1
HTC_TST_DSD Service Delivery Point (Facility) VCT: 1-9, Negative 2019 1,204
HTC_TST_DSD Service Delivery Point (Facility) VCT: 1-9, Positive 2019 25
HTC_TST_DSD Service Delivery Point (Facility) VCT: 10-14, Female, Negative 2019 262
HTC_TST_DSD Service Delivery Point (Facility) VCT: 10-14, Female, Positive 2019 5
HTC_TST_DSD Service Delivery Point (Facility) VCT: 10-14, Male, Negative 2019 255
HTC_TST_DSD Service Delivery Point (Facility) VCT: 10-14, Male, Positive 2019 5
HTC_TST_DSD Service Delivery Point (Facility) VCT: 15-19, Female, Negative 2019 7,167
HTC_TST_DSD Service Delivery Point (Facility) VCT: 15-19, Female, Positive 2019 511
HTC_TST_DSD Service Delivery Point (Facility) VCT: 15-19, Male, Negative 2019 13,537
HTC_TST_DSD Service Delivery Point (Facility) VCT: 15-19, Male, Positive 2019 467
HTC_TST_DSD Service Delivery Point (Facility) VCT: 20-24, Female, Negative 2019 7,167
HTC_TST_DSD Service Delivery Point (Facility) VCT: 20-24, Female, Positive 2019 511
HTC_TST_DSD Service Delivery Point (Facility) VCT: 20-24, Male, Negative 2019 13,537
HTC_TST_DSD Service Delivery Point (Facility) VCT: 20-24, Male, Positive 2019 467
HTC_TST_DSD Service Delivery Point (Facility) VCT: 50+, Female, Negative 2019 142
HTC_TST_DSD Service Delivery Point (Facility) VCT: 50+, Female, Positive 2019 11
HTC_TST_DSD Service Delivery Point (Facility) VCT: 50+, Male, Negative 2019 528
HTC_TST_DSD Service Delivery Point (Facility) VCT: 50+, Male, Positive 2019 59
HTC_TST_DSD Service Delivery Point (Facility) VCT: <1, Negative 2019 151
HTC_TST_DSD Service Delivery Point (Facility) VCT: <1, Positive 2019 3
HTC_TST_DSD Service Delivery Point (Facility)Other PITC: <1, Negative 2019 210
HTS_SELF_DSD HTS_SELF_N_DSD 2019 2,759
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Directly-Assisted 2019 222
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Female, Unassisted 2019 39
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Directly-Assisted 2019 181
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 15-19, Male, Unassisted 2019 72
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Directly-Assisted 2019 281
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Female, Unassisted 2019 49
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Directly-Assisted 2019 225
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 20-24, Male, Unassisted 2019 91
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Directly-Assisted 2019 56
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Female, Unassisted 2019 49
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Directly-Assisted 2019 450
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 25-29, Male, Unassisted 2019 91
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Directly-Assisted 2019 25
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Female, Unassisted 2019 24
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Directly-Assisted 2019 224
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 30-34, Male, Unassisted 2019 45
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Directly-Assisted 2019 25
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Female, Unassisted 2019 24
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Directly-Assisted 2019 224
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 35-39, Male, Unassisted 2019 45
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Directly-Assisted 2019 16
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Female, Unassisted 2019 14
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Directly-Assisted 2019 133
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 40-49, Male, Unassisted 2019 27
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Directly-Assisted 2019 10
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Female, Unassisted 2019 10
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Directly-Assisted 2019 91
HTS_SELF_DSD HTS_SELF_N_DSD_Age_Sex_HIVSelfTest 50+, Male, Unassisted 2019 18
HTS_SELF_DSD HTS_SELF_N_DSD_HIVSelfTest Directly-Assisted 2019 2,163
HTS_SELF_DSD HTS_SELF_N_DSD_HIVSelfTest Unassisted 2019 596
PMTCT_ART_DSD Already on ART at beginning of current pregnancy 2019 1,740
PMTCT_ART_DSD New on ART 2019 1,213
PMTCT_ART_DSD Number of HIV-positive pregnant women who received ART to reduce risk of mother-to-child-transmission (MTCT) during pregnancy 2019 2,953
PMTCT_ART_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 48,864
PMTCT_EID_DSD By infants who received a virologic test within 2 months of birth 2019 2,356
PMTCT_EID_DSD By infants who received their first virologic HIV test between 2 and 12 months of age 2019 593
PMTCT_EID_DSD Number of infants who had a virologic HIV test within 12 months of birth during the reporting period 2019 2,949
PMTCT_EID_DSD Sum of Infant Age disaggregates 2019 2,949
PMTCT_STAT_DSD By Age (Denominator): 10-14 2019 116
PMTCT_STAT_DSD By Age (Denominator): 20-24 2019 17,974
PMTCT_STAT_DSD By Age (Denominator): 50+ 2019 31
PMTCT_STAT_DSD By Age (Denominator): <15-19 2019 11,520
PMTCT_STAT_DSD By Age (Numerator): 10-14 2019 113
PMTCT_STAT_DSD By Age (Numerator): 15-19 2019 11,019
PMTCT_STAT_DSD By Age (Numerator): 20-24 2019 17,190
PMTCT_STAT_DSD By Age (Numerator): 50+ 2019 37
PMTCT_STAT_DSD By Number of known positives: 10-14 2019 3
PMTCT_STAT_DSD By Number of known positives: 15-19 2019 412
PMTCT_STAT_DSD By Number of known positives: 20-24 2019 645
PMTCT_STAT_DSD By Number of new negative: 10-14 2019 105
PMTCT_STAT_DSD By Number of new negative: 15-19 2019 10,321
PMTCT_STAT_DSD By Number of new negative: 20-24 2019 16,097
PMTCT_STAT_DSD By Number of new negative: 50+ 2019 39
PMTCT_STAT_DSD By Number of new positives: 10-14 2019 1
PMTCT_STAT_DSD By Number of new positives: 15-19 2019 286
PMTCT_STAT_DSD By Number of new positives: 20-24 2019 449
PMTCT_STAT_DSD Number of new ANC and L&D clients 2019 51,070
PMTCT_STAT_DSD Number of pregnant women with known HIV status (includes women who were tested for HIV and received their results) 2019 48,864
PMTCT_STAT_DSD PMTCT_STAT_D_DSD_Age_Sex 25-29, Female 2019 17,457
PMTCT_STAT_DSD PMTCT_STAT_D_DSD_Age_Sex 30-34, Female 2019 3,215
PMTCT_STAT_DSD PMTCT_STAT_D_DSD_Age_Sex 35-39, Female 2019 660
PMTCT_STAT_DSD PMTCT_STAT_D_DSD_Age_Sex 40-49, Female 2019 97
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex 25-29, Female 2019 16,696
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex 30-34, Female 2019 3,080
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex 35-39, Female 2019 635
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex 40-49, Female 2019 94
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Known at Entry Positive 2019 628
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Negative 2019 15,633
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 25-29, Female, Newly Identified Positive 2019 437
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Known at Entry Positive 2019 117
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Negative 2019 2,884
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 30-34, Female, Newly Identified Positive 2019 82
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Known at Entry Positive 2019 23
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Negative 2019 592
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 35-39, Female, Newly Identified Positive 2019 18
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Known at Entry Positive 2019 4
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Negative 2019 87
PMTCT_STAT_DSD PMTCT_STAT_N_DSD_Age_Sex_KnownNewResult 40-49, Female, Newly Identified Positive 2019 1
TB_ART_DSD Aggregated Age/Sex: Female 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 209
TB_ART_DSD Aggregated Age/Sex: Female <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 30
TB_ART_DSD Aggregated Age/Sex: Male 15+ (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 318
TB_ART_DSD Aggregated Age/Sex: Male <15 (Numerator: The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period) 2019 25
TB_ART_DSD The number of registered new and relapse TB cases with documented HIV-positive status who are on ART during TB treatment during the reporting period 2019 577
TB_PREV_DSD By Age/Sex (Denominator): 15+, Female 2019 4,604
TB_PREV_DSD By Age/Sex (Denominator): 15+, Male 2019 7,235
TB_PREV_DSD By Age/Sex (Denominator): <15, Female 2019 655
TB_PREV_DSD By Age/Sex (Denominator): <15, Male 2019 655
TB_PREV_DSD By Age/Sex (Numerator): 15+, Female 2019 4,146
TB_PREV_DSD By Age/Sex (Numerator): 15+, Male 2019 6,521
TB_PREV_DSD By Age/Sex (Numerator): <15, Female 2019 590
TB_PREV_DSD By Age/Sex (Numerator): <15, Male 2019 590
TB_PREV_DSD TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive 2019 1,304
TB_PREV_DSD TB_PREV_D_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive 2019 11,845
TB_PREV_DSD TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, Already, Positive 2019 1,185
TB_PREV_DSD TB_PREV_N_DSD_TherapyType_NewExArt_HIV IPT, Life-long ART, New, Positive 2019 10,662
TB_PREV_DSD The number of ART patients who completed a course of TB preventive therapy or at least 6 months of Isoniazid Preventive Therapy (IPT) during the reporting period 2019 11,847
TB_PREV_DSD The number of ART patients who were newly started on TB preventive therapy (including those who newly started on TB preventive therapy in this reporting period and those who started in the previous reporting period but had not been reported as they did not fulfill the minimum requirements for the previous reporting period) 2019 13,234
TB_STAT_DSD Aggregated Age/Sex: Female 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 494
TB_STAT_DSD Aggregated Age/Sex: Female 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 486
TB_STAT_DSD Aggregated Age/Sex: Female <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 63
TB_STAT_DSD Aggregated Age/Sex: Female <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 63
TB_STAT_DSD Aggregated Age/Sex: Male 15+ (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 755
TB_STAT_DSD Aggregated Age/Sex: Male 15+ (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 750
TB_STAT_DSD Aggregated Age/Sex: Male <15 (Denominator: Total number of registered new and relapsed TB cases, during the reporting period) 2019 66
TB_STAT_DSD Aggregated Age/Sex: Male <15 (Numerator: Number of registered new and relapsed TB cases with documented HIV status, during the reporting period) 2019 66
TB_STAT_DSD Number of registered new and relapsed TB cases with documented HIV status, during the reporting period 2019 1,365
TB_STAT_DSD Total number of registered new and relapsed TB cases, during the reporting period 2019 1,378
TX_CURR_DSD Age/Sex: 10-14 Female 2019 1,055
TX_CURR_DSD Age/Sex: 10-14 Male 2019 1,022
TX_CURR_DSD Age/Sex: 15-19 Female 2019 2,326
TX_CURR_DSD Age/Sex: 15-19 Male 2019 2,237
TX_CURR_DSD Age/Sex: 20-24 Female 2019 6,255
TX_CURR_DSD Age/Sex: 20-24 Male 2019 2,406
TX_CURR_DSD Age/Sex: 50+ Female 2019 12,019
TX_CURR_DSD Age/Sex: 50+ Male 2019 12,759
TX_CURR_DSD Age/Sex: <1 2019 260
TX_CURR_DSD Age/Sex: <1-9 2019 2,352
TX_CURR_DSD Number of adults and children receiving antiretroviral therapy (ART) 2019 146,487
TX_CURR_DSD Sum of age/sex disaggregates 2019 4,563
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive 2019 10,894
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive 2019 2,630
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive 2019 16,433
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive 2019 5,663
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive 2019 17,636
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive 2019 9,181
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive 2019 22,837
TX_CURR_DSD TX_CURR_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive 2019 18,522
TX_NEW_DSD Breastfeeding status 2019 610
TX_NEW_DSD By Age/Sex: 1-9 2019 143
TX_NEW_DSD By Age/Sex: 10-14 Female 2019 19
TX_NEW_DSD By Age/Sex: 10-14 Male 2019 19
TX_NEW_DSD By Age/Sex: 15-19 Female 2019 1,088
TX_NEW_DSD By Age/Sex: 15-19 Male 2019 948
TX_NEW_DSD By Age/Sex: 20-24 Female 2019 1,331
TX_NEW_DSD By Age/Sex: 20-24 Male 2019 948
TX_NEW_DSD By Age/Sex: 50+ Female 2019 22
TX_NEW_DSD By Age/Sex: 50+ Male 2019 156
TX_NEW_DSD By Age/Sex: <1 2019 54
TX_NEW_DSD Number of adults and children newly enrolled on antiretroviral therapy (ART) 2019 10,939
TX_NEW_DSD Pregnancy status 2019 2,278
TX_NEW_DSD Sum of Age/Sex disaggregates 2019 4,531
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Female, Positive 2019 668
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 25-29, Male, Positive 2019 274
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Female, Positive 2019 817
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 30-34, Male, Positive 2019 653
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Female, Positive 2019 797
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 35-39, Male, Positive 2019 689
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Female, Positive 2019 996
TX_NEW_DSD TX_NEW_N_DSD_Age_Sex_HIVStatus 40-49, Male, Positive 2019 1,317
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 6,449
TX_RET_DSD Aggregated Age/Sex: 15+ Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 6,407
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 4,347
TX_RET_DSD Aggregated Age/Sex: 15+ Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 4,314
TX_RET_DSD Aggregated Age/Sex: <15 Female (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 461
TX_RET_DSD Aggregated Age/Sex: <15 Female (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 444
TX_RET_DSD Aggregated Age/Sex: <15 Male (Denominator: Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up) 2019 460
TX_RET_DSD Aggregated Age/Sex: <15 Male (Numerator: Number of adults and children who are still alive and on treatment at 12 months after initiating ART) 2019 442
TX_RET_DSD Denominator by Status: Breastfeeding 2019 317
TX_RET_DSD Denominator by Status: Pregnant 2019 191
TX_RET_DSD Number of adults and children who are still alive and on treatment at 12 months after initiating ART 2019 11,607
TX_RET_DSD Numerator by Status: Breastfeeding 2019 348
TX_RET_DSD Numerator by Status: Pregnant 2019 189
TX_RET_DSD Total number of adults and children who initiated ART in the 12 months prior to the beginning of the reporting period, including those who have died, those who have stopped ART, and those lost to follow-up 2019 11,717
TX_TB_DSD Denominator: By Aggregated Age/Sex: <15, Female 2019 3,685
TX_TB_DSD Denominator: By Aggregated Age/Sex: <15, Male 2019 3,685
TX_TB_DSD Denominator: By Aggregated Age/Sex:15+, Female 2019 25,798
TX_TB_DSD Denominator: By Aggregated Age/Sex:15+, Male 2019 40,541
TX_TB_DSD Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Gene Xpert MTB / R if Assay 2019 43,679
TX_TB_DSD Denominator: By Diagnostic Test [Subdisagg of Specimen Sent]: Smear Only 2019 30,030
TX_TB_DSD Denominator: Number of ART patients who had a specimen sent for bacteriologic diagnosis of active TB disease 2019 73,709
TX_TB_DSD Number of ART patients who were screened for TB at least once during the reporting period 2019 73,709
TX_TB_DSD TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Negative, Positive 2019 65,612
TX_TB_DSD TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, Already, TB Screen - Positive, Positive 2019 735
TX_TB_DSD TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Negative, Positive 2019 7,297
TX_TB_DSD TX_TB_D_DSD_TBScreen_NewExistingART_HIV Life-long ART, New, TB Screen - Positive, Positive 2019 65
Cross Cutting Budget Categories and Known Amounts Total: $391,000
Gender: Gender Based Violence (GBV) $100,000
Post GBV Care
Renovation $156,000
Motor Vehicles: Purchased $135,000